Bluebird Bio reported $38.71M in Sales Revenues for its fiscal quarter ending in March of 2025.



Sales Change Date
Agios Pharmaceuticals USD 55.38M 10.64M Sep/2026
Alnylam Pharmaceuticals USD 1.46B 170M Sep/2026
Amgen USD 10.4B 300M Sep/2026
Arrowhead Research USD 450.82M 375.59M Sep/2026
Biogen USD 2.8B 60M Sep/2026
BioMarin Pharmaceutical USD 1.03B 40M Sep/2026
Gilead Sciences USD 8.3B 500M Sep/2026
Incyte USD 1.56B 110M Sep/2026
Ionis Pharmaceuticals USD 243M 25M Sep/2026
Moderna USD 1.31M 98.69M Sep/2026
Nektar Therapeutics USD 10.86M 10.95M Mar/2026
Novartis USD 14.52B 112M Sep/2026
Pfizer USD 16.6B 1.57B Sep/2026
PTC Therapeutics USD 357.8M 3.2M Sep/2026
Regeneron Pharmaceuticals USD 5.12B 830M Sep/2026
Sangamo BioSciences USD 356K 125K Jun/2024
Sarepta Therapeutics USD 381.4M 19.9M Sep/2026
Tectonic Therapeutic USD 0 0 Dec/2024
Ultragenyx Pharmaceutical USD 173M 41M Sep/2026
Vertex Pharmaceuticals USD 3.44B 110M Sep/2026